Relay Therapeutics Inc. Stock News

Relay Therapeutics Inc (RLAY) shares closed today at 1.7% above its 52 week low of $21.00, giving the company a market cap of $2B. The stock is currently down 27.5% year-to-date, down 61.3% over the past 12 months, and down 36.5% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 9.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 940.6% The company's stock price performance over the past 12 months lags the peer average by 298.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at

Wall Street analysts expect that Relay Therapeutics, Inc. (NASDAQ:RLAY) will post earnings of ($0.60) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Relay Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at ($0.48). The business is expected […] The post Relay Therapeutics, Inc. (NASDAQ:RLAY) Expected to Announce Earnings of -$0.60 Per Share appeared first on ETF Daily News .

Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.

Relay Therapeutics Inc. (NASDAQ:RLAY) shares, rose in value on Friday, 12/17/21, with the stock price up by 3.80% to the previous days close as strong demand from buyers drove the stock to $29.21. Actively observing the price movement in the last trading, the stock closed the session at $28.14, falling within a range of $27.45 Thinking About Buying Relay Therapeutics Inc. Stock? Heres What You Need To Know. Read More »

During the last session, Relay Therapeutics Inc. (NASDAQ:RLAY)s traded shares were 0.45 million. At the end of the trading day, the stocks price was $31.40, reflecting an intraday loss of -0.66% or -$0.21. The 52-week high for the RLAY share is $64.37, that puts it down -105.0 from that peak though still a striking 18.09% Relay Therapeutics Inc. (NASDAQ: RLAY) Stock Jumped 0.83% Over A Month Is There Any Hope Of A Gain? Read More »

Relay Therapeutics, Inc. (NASDAQ:RLAY) shares traded down 5.8% on Tuesday . The stock traded as low as $32.26 and last traded at $32.30. 4,235 shares traded hands during trading, a decline of 99% from the average session volume of 691,377 shares. The stock had previously closed at $34.28. RLAY has been the subject of several []

Relay Therapeutics, Inc. (NASDAQ:RLAY) SVP Thomas Catinazzo sold 22,500 shares of Relay Therapeutics stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $35.40, for a total value of $796,500.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Thomas []

Relay Therapeutics, Inc. (NASDAQ:RLAY) General Counsel Brian Adams sold 6,500 shares of Relay Therapeutics stock in a transaction on Monday, November 15th. The stock was sold at an average price of $35.42, for a total transaction of $230,230.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Brian […]

Relay Therapeutics, Inc. (NASDAQ:RLAY) SVP Thomas Catinazzo sold 22,500 shares of the stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $35.40, for a total value of $796,500.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Thomas Catinazzo […]

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed

Interim trial data suggests this innovative biotech start-up is on the right track.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, a

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed

CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed